← Back to patent-cliff list
Lidocaine/Allantoin/Glycyrrhetinic Acid/Vitamin E
Tier C — Watch / tradeLidocaine/Allantoin/Glycyrrhetinic Acid/Vitamin E
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SCNA, 11β-HSD1, PXR
Indications (approved)：肛裂, Pain, 疣
Regional status
US
-
EU
-
China
Phase II
2014-04-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lidocaine/Allantoin/Glycyrrhetinic Acid/Vitamin E?
Approved indications include: 肛裂, Pain, 疣.
When does the Lidocaine/Allantoin/Glycyrrhetinic Acid/Vitamin E patent expire?
No public expiry year is available for Lidocaine/Allantoin/Glycyrrhetinic Acid/Vitamin E yet; this page updates once verified.
How do I get a quote for Lidocaine/Allantoin/Glycyrrhetinic Acid/Vitamin E intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-12